Enter the vial size and the bacteriostatic water you added to get the concentration and the micrograms carried by each unit on a U-100 syringe. Cartalax's compound page states no dose and no route, so this page does the arithmetic, not the recommendation. The compound itself is covered in the Cartalax guide.
A 20 mg vial of Cartalax reconstituted with 2 mL of bacteriostatic water gives a concentration of 10 mg/mL, or 100 mcg per unit on a U-100 syringe.
Defaults: 20 mg is the most common labelled vial among the Cartalax tests on file, 21 Sep 2026 (37 of 52); 2 mL was chosen for simple arithmetic and is not a sourced volume. Peptigrity publishes no Cartalax dose, so the dose field starts empty.
Draw the syringe up to
Enter your own amount to see the draw. Add 2 mL of water to your 20 mg vial first.
Cartalax has 52 independent lab tests on file at Peptigrity, averaging 99.60% HPLC purity across the tests that report one. Purity is not net content: a clean certificate confirms what is in a vial, not how much. See the Cartalax lab-test records.
Cartalax is a synthetic tripeptide (Ala-Glu-Asp) from the Khavinson bioregulator family, researched for cartilage-targeted bioregulation, joint tissue support and connective tissue function. The compound page states that no human clinical trial of Cartalax, controlled or observational, has been published as of August 2026, and that the verifiable literature is a small set of in-vitro cell-culture studies of short peptides. Asked whether Peptigrity recommends a Cartalax dose, the page answers no. A calculator that printed one would be inventing it.
The table sets out what the Cartalax compound page states (Last Updated: August 2026).
| Question | What the compound page states | Evidence level |
|---|---|---|
| What is it? | A synthetic tripeptide (Ala-Glu-Asp) from the Khavinson bioregulator family, with a defined three-amino-acid sequence | Chemical identity |
| Proposed target? | Cartilage and connective tissue: chondrocyte function and cartilage matrix production | Khavinson-framework proposal |
| Human studies? | None published as of August 2026; claims of clinical use in osteoarthritis or joint recovery are not supported by a citable source | Preclinical (cell culture); Khavinson-group research |
| A route? | Not stated. The side-effects paragraph mentions injection-site reactions among community reports; that is safety text, not a route statement | None stated |
| An approved dose? | Not approved by the FDA, EMA, or any major Western regulator (as of August 2026) | None |
| A research dose? | None stated; Peptigrity does not recommend one | None — declined |
One practical consequence: the compound page notes that Ala-Glu-Asp differs from other tripeptides in the Khavinson cluster by single amino-acid substitutions, so a mislabeled vial would convert exactly the same way. Only a mass-spectrometry result on a certificate confirms the sequence. The arithmetic also works from the label, not the contents: the Cartalax fact sheet records 51 results comparing measured to labelled quantity, with a median of 106.5% of label (figures as of 2026-09-21).
The table converts reference quantities to syringe units at the default of 10 mg/mL (20 mg of Cartalax in 2 mL), and counts how many draws of each a vial holds. Every row is arithmetic, not a dose: read the units for the amount you already intend to measure.
| Quantity | Draw at 10 mg/mL | Volume | Draws from a 10 mg vial | Draws from a 20 mg vial |
|---|---|---|---|---|
| 100 mcg | 1.0 units | 0.01 mL | 100 | 200 |
| 250 mcg | 2.5 units | 0.025 mL | 40 | 80 |
| 500 mcg | 5.0 units | 0.05 mL | 20 | 40 |
| 1 mg | 10.0 units | 0.10 mL | 10 | 20 |
| 2 mg | 20.0 units | 0.20 mL | 5 | 10 |
The same Cartalax quantity lands on a different mark depending on how much water went into the vial. Read down the column for the concentration you actually mixed; a units figure carried across from another column is simply wrong.
| Quantity | At 20 mg/mL (20 mg + 1 mL) | At 10 mg/mL (20 mg + 2 mL) | At 4.0 mg/mL (20 mg + 5 mL) |
|---|---|---|---|
| 100 mcg | 0.5 units | 1.0 units | 2.5 units |
| 250 mcg | 1.3 units | 2.5 units | 6.3 units |
| 500 mcg | 2.5 units | 5.0 units | 12.5 units |
| 1 mg | 5.0 units | 10.0 units | 25.0 units |
| 2 mg | 10.0 units | 20.0 units | 50.0 units |
Every cell is the same arithmetic: units = (quantity in mg ÷ concentration in mg/mL) × 100 on a U-100 syringe. More water spreads the same mass over more units, which is the fix when a small quantity would otherwise sit at two or three units, where a one-unit misread is a large error.
Each Cartalax vial holds as many draws as its labelled mass divided by the quantity per draw; the water volume changes nothing about it. The grid counts draws, not weeks — this page states no frequency.
| Vial size | At 100 mcg | At 250 mcg | At 500 mcg | At 1 mg | At 2 mg |
|---|---|---|---|---|---|
| 10 mg | 100 | 40 | 20 | 10 | 5 |
| 20 mg | 200 | 80 | 40 | 20 | 10 |
The labelled mass is not a guarantee of the mass in your vial: net content is a separate measurement from purity, and certificates on file often measure a few percent above or below the label.
No label sets a diluent volume for research-grade Cartalax, and the compound page states none, so the volume is a choice; the 2 mL default here was picked for simple arithmetic. The one decision with real consequences is resolution: a 20 mg vial in 2 mL is 10 mg/mL, where each unit carries 100 mcg and a small quantity sits at one or two units. The fix is more water: 5 mL in the same vial is 4 mg/mL, or 40 mcg per unit. The technique is covered once, elsewhere: reconstituting peptides step by step and the bacteriostatic water guide. Storage and in-use guidance there is general peptide guidance, not a Cartalax-specific finding.
Pinealon, Cartalax and Testagen share one calculator template. The table gives each one's structure and proposed target as its own compound page states them (each Last Updated: August 2026), and the most common labelled vial among its tests on file on 21 Sep 2026.
| Compound | Structure | Proposed target tissue | Most common labelled vial | Calculator |
|---|---|---|---|---|
| Pinealon | Tripeptide (Glu-Asp-Arg) | Pineal / brain | 20 mg (36 of 71 tests) | Pinealon calculator |
| Cartalax | Tripeptide (Ala-Glu-Asp) | Cartilage / connective tissue | 20 mg (37 of 52 tests) | This page |
| Testagen | Tetrapeptide (Lys-Glu-Asp-Gly) | Testis / reproductive | 20 mg (18 of 22 tests) | Testagen calculator |
None of the three compound pages states a dose or a route. Because the vials share a size, the arithmetic is the same for each; what differs is identity, which only mass spectrometry settles. The wider family is in the bioregulators category and the science of Khavinson bioregulators.
Cartalax is not approved by the FDA, EMA, or any major Western regulator as of August 2026. The compound page states it is not on the FDA's active Section 503A/503B Category-2 bulk-substances list and was not among the peptides addressed in the FDA's April 2026 Category-2 actions or the July 2026 Pharmacy Compounding Advisory Committee meeting, so no U.S. compounding pathway applies to it. It is used in Russian clinical and research contexts, and is sold as a research-use-only compound by third-party laboratories. Background: FDA peptide regulation 2025–2026.
Independent test records: Cartalax lab tests. Tracked prices: Cartalax price per milligram.
It depends on the concentration. At the page default of 10 mg/mL (a 20 mg vial with 2 mL of water), each unit on a U-100 syringe carries 100 mcg, so 1 mg (1,000 mcg) is 10 units (0.1 mL). A 10 mg vial with the same 2 mL is 5 mg/mL, and 1 mg is 20 units (0.2 mL). A units figure quoted without a concentration cannot be used.
There isn't one. Cartalax is not approved by any major Western regulator, no human clinical trial of it has been published as of August 2026, and Peptigrity does not recommend a dose. This calculator converts a quantity you already have in mind into syringe units; it does not supply the quantity.
No. The Cartalax compound page places them in different mechanism families: Cartalax is proposed to act through epigenetic gene-expression modulation in connective tissue, while BPC-157 is a 15-amino-acid peptide proposed to act through angiogenesis, growth-factor signaling and tissue-repair pathways. It adds that BPC-157 has substantially more independent research support.
The Cartalax compound page states no route. Its side-effects paragraph says injection-site reactions are the most common report in preclinical data and community-reported research use; that is safety text, not a route statement, and this page does not treat it as one. The calculator converts the mass in a reconstituted vial into syringe units because that is the arithmetic people ask for; it establishes nothing about route.
Because 20 mg is the most common labelled size among the Cartalax tests on file at Peptigrity: 37 of 52 on 21 Sep 2026, with 10 mg the next most common. The 2 mL of water is a round number chosen for simple arithmetic, not a sourced instruction.
With an independent certificate of analysis: HPLC for purity and mass spectrometry for identity. The compound page calls mass spectrometry essential for Cartalax because it shares amino-acid composition with other Khavinson tripeptides, which differ from it by single amino-acid substitutions.